Call for Speaker Proposals

第2屆
Oncology Clinical Trials
-癌治療藥臨床試驗學會-
藉由改善臨床試驗，促進開發癌治療藥
2月21日∼23日

由於癌分子生物學研究近幾年獲得驚人的成果，在癌治療藥開發的領域，產生以前沒有的許多新標的。許多因應這樣標的的藥劑，已經進入臨床階段，如火如荼進行因應各種療法的癌治療藥臨床試驗。癌治療藥臨床試驗成功的主因很多，最重要的是臨床前數據的質能否達到導出可驗證的假設之水準。此外，與生物統計學、科學、組織、法規、倫理、經濟等有關的主因，在醫藥品臨床開發時具有重要的意義。

Who should attend: Scientists, biostatisticians, project managers, research investigators and other specialists involved in oncology clinical trials

Topics will include, but are not limited to:

• Translational clinical trials in oncology
• Evaluating pre-clinical evidence to avoid clinical development failures
• Molecular imaging in cancer clinical trials
• Prescreening patients for somatic mutations before randomization
• Biomarker-driven clinical trials
• Companion diagnostics in oncology clinical trials
• Advanced methodology for dose-finding clinical trials
• Dose finding for �gnontoxic�h drug
• Pharmacodynamic biomarkers and their use in clinical trials
• Role of randomization in middle development
• How to use surrogate outcomes in the light of lack of biomarker validation
• Regulatory and legal challenges and solutions
• Safety issues in cancer clinical trials
• Ways to increase patient enrollment
• Ethical issues related to biomarker use for patient selection (what is the threshold?)
• Cost effectiveness of clinical trials in the US and abroad
• Joint development: Industry-academic collaboration (identification (who takes responsibility), shared intellectual property, etc.)

The deadline for submission is July 29, 2011.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are
offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.